InflaRx raises $150M to advance anti-inflammatory drug pipeline
What's the deal? InflaRx, a German biopharmaceutical company listed on Nasdaq, has priced a $150M underwritten offering of 75 million ordinary shares at $2.00 per share. The company plans to use the proceeds to advance its pipeline of anti-inflammatory therapeutics targeting the complement system and for general corporate purposes.
The offering, announced on May 6, 2026, is expected to close on May 7. Guggenheim Securities is acting as lead bookrunner, with Oppenheimer & Co. and LifeSci Capital also serving as bookrunners.
Why now? The financing drew participation from a mix of new and existing investors, including TCGXDealroom has a profile for this one. Try Dealroom →, a large healthcare-dedicated fund, alongside Farallon Capital ManagementDealroom has a profile for this one. Try Dealroom →, Columbia Threadneedle Investments, Great Point Partners, and several other institutional players. That breadth of investor interest suggests confidence in InflaRx's pipeline at this stage.
InflaRx, headquartered in Jena, Germany, develops anti-C5a and anti-C5aR therapies — highly specific inhibitors designed to control inflammation. The capital injection should give it runway to push these programmes forward.
What could go wrong? At $2.00 per share, the offering price signals the company is still in early-to-mid-stage territory where clinical and regulatory risk looms large. Biotech firms at this valuation level often face dilution concerns, and there's no guarantee the pipeline will deliver commercially viable products.
The signal: InflaRx is classified as a "breakout" stage company on Dealroom, suggesting it has moved beyond pure early-stage risk — yet the $2.00 share price underscores how far it still has to go to translate clinical progress into market confidence. The participation of dedicated healthcare funds such as TCGX and multi-strategy heavyweights like Farallon Capital Management points to specialist conviction in complement-targeting therapeutics at a time when generalist investors remain cautious on small-cap biopharma.
Read more: inflarx.de
